NEW YORK – Decentralized molecular testing is gaining ground for SARS-CoV-2 diagnosis in India. Due in part to a robust anti-tuberculosis campaign, the testing modality has made inroads into the country's complex and tiered healthcare system during the past decade. Now, decentralized platforms from firms like MolBio Diagnostics and Cepheid, as well as newcomer Tata Group, are starting to play a significant role in COVID-19 diagnostic testing in India as well.